Multi-technique imaging of bone metastases: spotlight on PET-CT. Issue 7 (July 2016)

• Record Type: Journal Article
• Authors: Azad, Gurdip K.; Cook, Gary J.
• Is Part Of: Clinical radiology. Volume 71:Issue 7(2016)
• Page Start: 620
• Page End: 631
• Publication Date: 2016-07
• Subjects: Medical radiology -- Periodicals; Radiotherapy -- Periodicals; Radiotherapy -- Periodicals; Radiology -- Periodicals; Societies, Medical -- Periodicals; Medical radiology; Radiotherapy; Electronic journals; Periodicals; 616.0757
• DOI: 10.1016/j.crad.2016.01.026
• Languages: English
• ISSNs: 0009-9260

Abstract

Abstract : There is growing evidence that molecular imaging of bone metastases with positron-emission tomography (PET) can improve diagnosis and treatment response assessment over current conventional standard imaging methods, although cost-effectiveness has not been assessed. In most cancer types, 2-[ 18 F]-fluoro-2-deoxy-d -glucose ( 18 F-FDG)-PET is an accurate method for detecting bone metastases. For example, in breast cancer, combined 18 F-FDG-PET and computed tomography (CT) is more sensitive at detecting bone metastases than 99m technetium (Tc)-labelled diphosphonate planar bone scintigraphy (BS) and there is increasing evidence to support the use of serial 18 F-FDG-PET for the assessment of osseous response to treatment. Preliminary data suggest improved diagnostic accuracy of 18 F-FDG-PET-CT in a number of other malignancies including lung, thyroid, head and neck, gastro-oesophageal cancers, and osteosarcoma. As a bone-specific tracer, there is accumulating evidence to support the use of sodium 18 F-fluoride ( 18 F-NaF) PET-CT in the diagnosis of skeletal metastases in breast and prostate cancer, although relatively little data are available to support its use for assessment of treatment response. In prostate cancer, 11 C-choline and 18 F-choline PET-CT have better specificities than 18 F-NaF-PET-CT, but equivalent sensitivities in the detection of bone metastases. We review the current literature for staging and response assessment of bone metastases in different cancers.